In the last trading session, 2.27 million shares of the Elevation Oncology Inc (NASDAQ:ELEV) were traded, and its beta was 1.29. Most recently the company’s share price was $0.71, and it changed around $0.04 or 6.24% from the last close, which brings the market valuation of the company to $42.05M. ELEV currently trades at a discount to its 52-week high of $5.83, offering almost -721.13% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has risen by an impressive 29.58% since then. We note from Elevation Oncology Inc’s average daily trading volume that its 10-day average is 7.34 million shares, with the 3-month average coming to 1.86 million.
Elevation Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended ELEV as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. Elevation Oncology Inc is expected to report earnings per share of -0.22 for the current quarter.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Instantly ELEV has showed a green trend with a performance of 6.24% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.9800 on recent trading dayincreased the stock’s daily price by 27.55%. The company’s shares are currently up 26.43% year-to-date, but still up 9.36% over the last five days. On the other hand, Elevation Oncology Inc (NASDAQ:ELEV) is 11.14% up in the 30-day period. We can see from the shorts that 6.44 million shares have been sold at a short interest cover period of 6.58 day(s).
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 92.11% from its current value. Analyst projections state that ELEV is forecast to be at a low of $8 and a high of $10.
Elevation Oncology Inc (ELEV) estimates and forecasts
Elevation Oncology Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -73.36 percent over the past six months and at a 37.31% annual growth rate that is well above the industry average of 16.50%.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -52.56%.
ELEV Dividends
Elevation Oncology Inc’s next quarterly earnings report is expected to be released in February.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.27% of Elevation Oncology Inc shares, and 83.88% of them are in the hands of institutional investors. The stock currently has a share float of 84.11%. Elevation Oncology Inc stock is held by 93.0 institutions, with LOGOS GLOBAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 6.5234% of the shares, which is about 3.85 million shares worth $10.39 million.
FARALLON CAPITAL MANAGEMENT LLC, with 6.0971% or 3.6 million shares worth $9.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.64 shares worth $1.16 million, making up 2.77% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.32 shares worth around $0.94 million, which represents about 2.23% of the total shares outstanding.
